Setup

SANUWAVE Health makes UltraMIST, the only FDA-cleared non-contact ultrasound wound therapy device in the US. It bills under CPT 97610, a Category 1 procedure code in the Medicare physician fee schedule. The stock is down 50% over the past year, tracking MiMedx (-48%) and Organogenesis (-48%) in lockstep — both skin substitute companies being destroyed by a CMS reimbursement crackdown that does not apply to SANUWAVE's product or billing pathway.

What the filing says

SANUWAVE filed an 8-K on March 26, 2026 (earnings release) alongside its 10-K. Key numbers from FY2025:

Revenue: $44.1M (+35% YoY). Q4 revenue $13.4M, an all-time quarterly record. Gross margin expanded to 77% from 75%.

Unit surge: 255 UltraMIST systems sold in Q4 2025, up from 155 in Q3 and 135 in Q4 2024 — a +89% YoY acceleration. CEO Morgan Frank: "Significant numbers of large, skilled distributors and resellers who had been focusing on skin subs and allografts have become interested in repping UltraMIST."

FY2026 guidance initiated: $51-55M (+16-25% YoY). First forward guidance since the restatement. Wide range reflects CMS transition uncertainty.

Consumable lag: Consumable revenue grew only 10.6% YoY in Q4 despite the system surge — mix dropped to 48.7% of Q4 revenue from 58% for the full year. New installations take 1-2 quarters to generate mature consumable demand. Frank acknowledged headwinds: "some customers going out of business and others reducing patient volumes in response to an aggressive audit environment."

True levered FCF: -$1.8M. Operating cash flow $3.9M minus capex $1.9M minus cash interest $3.7M. The $13.6M Adjusted EBITDA is not cash. The business needs roughly $50M+ in revenue to turn FCF positive.

Governance: Material restatement covering 7 periods. Sales tax nexus failure 2022-2025 ($4.9M accrued liability, minimum-of-range methodology) and $300K revenue overstatement on extended warranties. Material weaknesses in internal controls not remediated as of December 31, 2025. Auditor switched from Marcum ($13M PCAOB fine, sanctioned) to Baker Tilly (Top 10). Clawback analysis triggered.

What the market thinks

The stock at $18.85 prices a roughly -5% expected return. Three things the market believes:

1. CMS crackdown hurts SNWV. The stock correlates almost perfectly with MDXG and ORGO over the past year. The market treats all wound care as one basket.

2. Governance is disqualifying. Seven-period restatement, unresolved material weaknesses, negative FCF. 11% short interest, 10.6 days to cover.

3. Consumables aren't converting. Q4 consumable mix dropped to 48.7%. The razor/blade model is unproven at this installation rate.

At 3.2x FY2026E revenue and 12.6x trailing Adjusted EBITDA, the stock isn't obviously cheap on multiples. The discount is in the multiple compression — a clean, growing medtech monopoly at 77% gross margins would trade 5-8x revenue.

Why the gap exists

The market has the CMS sensitivity sign wrong.

Medicare Part B spending on skin substitutes grew from $256M in 2019 to over $10B in 2024 — a 40x increase in five years. OIG found traditional Medicare spent $2.9B in Q3 2024 alone. A couple in Arizona pled guilty to orchestrating a $1.2 billion fraud scheme involving medically unnecessary wound grafts. CMS responded with a rule (CMS-1832-F, effective January 1, 2026) that reclassifies most skin substitutes from ASP+6% to a flat $127.14 per square centimeter. When ASPs ranged from $12 to $5,900 per square centimeter — per MiMedx's own 10-K — the high-priced products saw cuts of 97%. CMS projects $19.6B in savings.

This hit skin substitute companies with four simultaneous shocks on January 1: the flat rate, a new prior authorization model (WISeR) in six states, an LCD withdrawal on December 24 causing coverage uncertainty, and discarded product guidance on December 30 causing what Organogenesis CEO Gary Gillheeney called "clinician confusion and material disruption in the market."

UltraMIST is not a skin substitute. It bills under CPT 97610, a procedure code for non-contact low-frequency ultrasound therapy. This is confirmed by: the CMS Medicare Coverage Database (Article A56175, which classifies CPT 97610 as "low frequency, non-contact, non-thermal ultrasound" — a procedure code, not a product code), Reed Smith legal analysis of the final rule (confirming the reclassification targets biologicals, HCT/Ps, and skin substitute devices — not therapeutic procedure codes), Health Law Alliance enforcement analysis (March 2026, focused specifically on "cellular and tissue-based product claims" with no mention of ultrasound therapy), and SANUWAVE's own press release (November 3, 2025) confirming rates "remain materially unchanged for 2026."

Four independent competitors confirm the disruption SANUWAVE describes:

MiMedx (MDXG): Guiding FY2026 revenue down 14-19% ($340-360M vs $419M). CEO Joseph Capper, five months before SANUWAVE's observation, predicted on the Q3 2025 call: "Expect to see number of competitors decrease in wound care market when reimbursement comes into effect as certain business models become significantly less attractive."

Organogenesis (ORGO): Guiding Q1 2026 revenue down roughly 50% YoY, full-year down 25-38%. Cash fell from $136M to $94M in FY2025, operating cash flow was negative $10.3M, and the $75M revolving credit facility expires August 2026. On the Q4 call, an analyst asked about "smaller competitors maybe exiting market" — the buy side is independently tracking this.

Coloplast/Kerecis (CLPBY): CEO Lars Rasmussen (Q1 2026 call): "See pretty large number of competitors not able to meet price criteria." Kerecis growth guidance cut from 20% to 10%. "Negative growth in outpatient setting."

Smith & Nephew (SNN): Reported "slowdown in skin subs physician office outpatient." Expects $20-40M incremental wound reimbursement headwind.

The gap persists because: (1) only two analysts cover SNWV — information efficiency is low; (2) algorithmic strategies bucket all wound care tickers together; (3) the governance overhang gives fundamental sellers a reason to sell that has nothing to do with CMS.

What is NOT confirmed: that displaced reps are specifically switching to UltraMIST. No peer names SANUWAVE as a beneficiary. The 255-unit Q4 surge is consistent with the narrative but could partly reflect reseller channel loading — SANUWAVE does not disclose the reseller-vs-direct split.

Risks

1. Governance spiral (20% probability). Another restatement, higher sales tax liability, or Nasdaq compliance issues. Material weaknesses are unresolved. Baker Tilly's first full audit cycle could surface problems Marcum missed. If this materializes, estimated -27% contribution to stock price regardless of other factors.

2. Consumable conversion failure (10% probability). The 255 Q4 system installations don't generate recurring consumable demand — either reseller channel loading or CMS audit environment suppresses patient volumes longer than expected. If Q1 consumables come in below $6M (from $6.5M in Q4), the razor/blade model is questioned at scale.

3. CMS extends to CPT 97610 (< 5% probability). Would require a separate rulemaking cycle — proposed rule, comment period, final rule — minimum 12-18 months. No evidence of CMS interest. The policy rationale (combating fraud in skin substitute billing, backed by the $1.2B Arizona prosecution) does not extend to procedural ultrasound therapy. Low probability but thesis-ending.

4. Negative FCF persists. The business needs ≈$50M revenue to turn FCF positive. If growth decelerates, the company remains dependent on its JPMorgan credit facility. Cash is $12M — not distressed, but not self-funding.

5. Affiliated insider selling. Manchester Management sold $5.1M in December 2025 at ≈$30.70 — the most informed affiliated party exited 40% above current price. This is an early-stage fund, not management, but it's the largest insider transaction in SNWV's recent history. No management selling.

Catalysts

Proxy DEF 14A (by April 30, 2026). CEO compensation, insider ownership, clawback outcome. First governance data point.

Q1 2026 10-Q (~May 15, 2026). The critical filing. Three things to watch: (1) consumable revenue — does it recover above $7M from Q4's $6.5M? (2) material weakness language — is Baker Tilly signaling remediation progress? (3) revenue vs $9.6-10.3M guidance. Consumable mix and ICFR language matter more than the revenue headline.

ORGO Q1 results (~May 2026). If Organogenesis reports the guided -50% Q1 decline, it independently confirms the CMS disruption severity. ORGO's revolving credit expires August 2026 — if they face a liquidity event, it further validates the crackdown's permanence.

Q2 2026 10-Q (~August 2026). Two consecutive clean filings with MW remediation progress would materially de-risk the governance factor.

What would change our mind

The CMS thesis breaks if: CPT 97610 rates are cut in CY2027 proposed rulemaking (monitor October 2026 NPRM); or SNWV revenue decelerates below 10% growth despite the peer disruption.

The governance thesis breaks if: Q1 10-Q discloses a new material weakness or sales tax accrual increases above $7.5M.

The consumable thesis breaks if: Q1 consumable revenue is below $6.0M while system placements remain elevated.

We would become more bullish if: Q1 consumables exceed $7.5M, material weakness remediation is confirmed, or a third analyst initiates coverage.

Evidence